Moreover, two larger sample size data set, shown in Fig. 2b,c, suggested that SGO2 overexpression correlated with poor survival outcome in high grade glioma patients with statistical significance (TCGA, n = 343, p < 1 × 10–15 by log-rank test, 95% CI 2.88–5.30, hazard ratio 3.91; CGGA, n = 455, p = 4.07 × 10–11 by log-rank test, 95% CI 1.66–2.60, hazard ratio 2.08). Here, SGO2 is linked to central nervous system cancer.